featured-image

Grandbrothers Shares of Vivani Medical ( NASDAQ: VANI ) added ~10% premarket Thursday after the MedTech company said that the U.S. FDA lifted the clinical hold on NPM-119, a medical implant designed to deliver GLP-1 receptor agonist exenatide over a longer period of time.

The decision allows Alameda, California-based Vivani ( VANI ) to start its Phase 1 LIBERATE-1 study designed to evaluate NPM-119 in patients with type 2 diabetes over 12 weeks. The miniature implant, containing diabetes therapy exenatide marketed as Byetta, was developed to address non-adherence and tolerability issues linked to oral and injectable type 2 diabetes drugs. LIBERATE-1 will also mark the first clinical application of the company’s NanoPortal implant platform technology.



Additionally, Vivani ( VANI ) said it will use data from LIBERATE-1 to plan studies for NPM-115, another exenatide-based implant targeting weight management that has indicated weight loss compared to Novo Nordisk’s ( NVO ) popular GLP-1 agonist semaglutide. More on Vivani Medical Seeking Alpha’s Quant Rating on Vivani Medical Historical earnings data for Vivani Medical Financial information for Vivani Medical.

Back to Health Page